Horizon Technology Finance Corporation 4.875% Notes due 2026 Stock (NYSE: HTFB)

Horizon Technology Finance Corporation 4.875% Notes due 2026 Stock (NYSE:HTFB), Trade Ideas

Horizon Technology Finance Corporation 4.875% Notes due 2026

<p>The common shares are expected to be offered by Novelis&#39; sole shareholder (a wholly owned subsidiary of Hindalco Industries Limited). Novelis will not receive any proceeds from the sale of common shares by its sole shareholder.</p>
<p>Novelis is a subsidiary of Hindalco Industries Limited, a&nbsp;metals flagship company of the Aditya Birla Group, a multinational conglomerate based in&nbsp;Mumbai.</p>


News

IPOs

Novelis Files Registration Statement For Proposed IPO; Intends To List Its Common Shares On NYSE Under Ticker Symbol 'NVL'

<p><strong>Paysafe Ltd </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>)<strong> </strong>reported its first-quarter financial results after the bell Monday. Here's a <a href="https://www.benzinga.com/pressreleases/24/05/b38800111/paysafe-reports-first-quarter-2024-results-reaffirms-full-year-outlook">look at the highlights. </a></p>
<p><strong>The Details:</strong> Paysafe reported first-quarter adjusted earnings of 57 cents per share, beating the 10 cent analyst consensus estimate.</p>
<p>Quarterly sales came in at $417.7 million, reflecting a 7% growth in total payment volume and beating the $408.25 million estimate.</p>
<p>Revenue from the Merchant Solutions segment increased 11%, reflecting double-digit growth in e-commerce as well as growth from small and medium-sized businesses driven by initiatives to expand sales capabilities and optimize the portfolio. </p>
<p>Revenue from the Digital Wallets segment increased 5% as reported and 4% in constant currency, reflecting growth from gambling merchants as well as ongoing initiatives related to product and consumer engagement.</p>
<p>&#8220;We are off to a great start this year, delivering 8% year-over-year revenue growth in the first quarter, reinforcing that our strategic initiatives and associated investments are driving momentum in the business and setting us up for long-term success. We remain confident in our financial outlook for this year, which reflects stronger underlying revenue performance, anchored by improved operational execution,&#8221; <strong>Bruce Lowthers</strong>, CEO of Paysafe, said.</p>
<p><strong>Outlook: </strong> Paysafe reaffirmed its full-year 2024 revenue guidance of between $1.688 billion and $1.712 billion, versus the $1.7 billion analyst consensus estimate.</p>
<p><strong>PSFE Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Paysafe shares are up 7.21% after-hours at $16.80 at the time of publication Monday.</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/24/05/38795608/gamestop-leads-roaring-rally-whats-going-on-with-meme-stocks"><em>GameStop Leads Roaring Rally: What&#8217;s Going On With Meme Stocks?</em></a></p>
<p><em>Photo: Buffik from Pixabay</em></p>


Earnings

After-Hours Center

Movers

PSFE

Paysafe Stock Climbs On Q1 Results: Here's Why

Earnings Beats

FBRX

CORRECTION: Forte Biosciences Q1 GAAP EPS $(0.16) Beats $(0.17) Estimate

CHCI

Comstock Inks Four New Leases At The Hartford Building, Virginia

<p>Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.78) by 8.97 percent.</p>


Earnings Misses

TSBX

Turnstone Biologics Q1 EPS $(0.85) Misses $(0.78) Estimate

<p>Guardion Health Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHSI#NASDAQ">GHSI</a>) reported quarterly losses of $(3.71) per share which missed the analyst consensus estimate of $(0.88) by 321.59 percent. This is a 983.33 percent decrease over earnings of $0.42 per share from the same period last year.  The company reported quarterly sales of $3.00 million which missed the analyst consensus estimate of $3.12 million by 3.86 percent.  This is a 5.85 percent decrease over sales of $3.19 million the same period last year.</p>


GHSI

Guardion Health Sciences Q1 EPS $(3.71) Misses $(0.88) Estimate, Sales $3.00M Miss $3.12M Estimate

<p>Norman Fan&nbsp;will assume the interim position of overseeing the financial and reporting functions of the Company.&nbsp;</p>


Management

HSAI

Hesai Group Louis T. Hsieh Has Resigned From His Positions As Global CFO And Board Director For Personal And Family Reasons, Effective Today

HBNC

Horizon Bancorp Appoints John Stewart As CFO

<p>4 analysts have shared their evaluations of Fulcrum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FULC#NASDAQ">FULC</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.25, a high estimate of $17.00, and a low estimate of $14.00. Observing a 12.96% increase, the current average has risen from the previous average price target of $13.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634070_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Fulcrum Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$14.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Fulcrum Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Fulcrum Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Fulcrum Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fulcrum Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/FULC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Fulcrum Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Get to Know Fulcrum Therapeutics Better</h2>
<p>Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.</p>
<h3>Breaking Down Fulcrum Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Fulcrum Therapeutics displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately <strong>27.15%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Fulcrum Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-2842.25%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Fulcrum Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-10.09%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-9.23%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Fulcrum Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.05</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

FULC

Deep Dive Into Fulcrum Therapeutics Stock: Analyst Perspectives (4 Ratings)

<p>10 analysts have shared their evaluations of Paycor HCM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYCR#NASDAQ">PYCR</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Paycor HCM, revealing an average target of $28.2, a high estimate of $42.00, and a low estimate of $19.00. This current average has increased by 9.05% from the previous average price target of $25.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634063_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>A comprehensive examination of how financial experts perceive Paycor HCM is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabriela Borges</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Bhavin Shah</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$19.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$20.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$22.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$19.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Mark Marcon</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$42.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Paycor HCM. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Paycor HCM compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Paycor HCM's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Paycor HCM's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PYCR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Paycor HCM analyst ratings.</strong></a></p>
<h2>Delving into Paycor HCM's Background</h2>
<p>Paycor HCM provides payroll and human capital management solutions to small and midsize clients in the United States via a software-as-a-service model. Alongside core payroll functionality, the firm's platform offers a suite of HCM solutions including talent management and time and attendance software, third-party integration capabilities, and industry-specific configurations. The firm targets customers with 10-1,000 employees and had over 30,000 customers as of June 2023.</p>
<h3>Paycor HCM: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Paycor HCM's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>15.81%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Industrials sector.</p>
<p><strong>Net Margin:</strong> Paycor HCM's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>3.31%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>0.48%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Paycor HCM's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.22%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Paycor HCM's debt-to-equity ratio is below the industry average at <strong>0.01</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PYCR

Analyst Scoreboard: 10 Ratings For Paycor HCM

<p>Throughout the last three months, 4 analysts have evaluated Lifetime Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCUT#NASDAQ">LCUT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.0, a high estimate of $13.50, and a low estimate of $11.00. This current average has increased by 20.0% from the previous average price target of $10.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634055_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Lifetime Brands's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Linda Bolton Weiser</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.50</td>
<td>$9.50</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$11.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Lifetime Brands. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lifetime Brands compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Lifetime Brands's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Lifetime Brands's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LCUT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Lifetime Brands analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Lifetime Brands</h2>
<p>Lifetime Brands Inc is a U.S. based company that designs, sources, and sells branded kitchenware, tableware, and other products used in the home and markets its products under brands such as Farberware, KitchenAid, Mikasa, and others. The company markets and sells its products principally on a wholesale basis to retailers. It also markets and sells a limited selection of its products directly to consumers through its Pfaltzgraff, Mikasa, Fred, and Friends, Built NY, and others. Its products include kitchen tools, gadgets, cutlery, dinnerware, and glassware. The segments of the company are the U.S. and International. It derives a majority of its revenue from the U.S. segment. The company derives maximum revenue from Kitchenware products.</p>
<h3>Unraveling the Financial Story of Lifetime Brands</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Lifetime Brands's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately <strong>-1.88%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Lifetime Brands's net margin excels beyond industry benchmarks, reaching <strong>1.33%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>1.18%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Lifetime Brands's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.4%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> Lifetime Brands's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.23</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


LCUT

The Analyst Landscape: 4 Takes On Lifetime Brands

<p>Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $15.4, along with a high estimate of $18.00 and a low estimate of $14.00. Witnessing a positive shift, the current average has risen by 24.9% from the previous average price target of $12.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634032_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive CareDx is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Connor Chamberlain</td>
<td>Craig-Hallum</td>
<td>Maintains</td>
<td>Buy</td>
<td>$15.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to CareDx. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of CareDx compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of CareDx's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into CareDx's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CDNA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on CareDx analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into CareDx's Background</h2>
<p>CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.</p>
<h3>Key Indicators: CareDx's Financial Health</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, CareDx faced challenges, resulting in a decline of approximately <strong>-20.41%</strong> in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> CareDx's net margin is impressive, surpassing industry averages. With a net margin of <strong>-180.11%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CareDx's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-36.03%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> CareDx's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-24.4%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.13</strong>, CareDx adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CDNA

Navigating 5 Analyst Ratings For CareDx

<p>Throughout the last three months, 7 analysts have evaluated Hess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $182.86, a high estimate of $210.00, and a low estimate of $156.00. Observing a 4.58% increase, the current average has risen from the previous average price target of $174.86. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634022_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>The perception of Hess by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$164.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$173.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$205.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ryan Todd</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$172.00</td>
<td>$169.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$156.00</td>
<td>$152.00</td>
</tr>
<tr>
<td>Nitin Kumar</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hess. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Hess compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Hess's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hess's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/HES/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Hess analyst ratings.</strong></a></p>
<h2>Delving into Hess's Background</h2>
<p>Hess is an independent oil and gas producer with key assets in the Bakken Shale, Guyana, the Gulf of Mexico, and Southeast Asia. At the end of 2023, the company reported net proved reserves of 1.4 billion barrels of oil equivalent. Net production averaged 391 thousand barrels of oil equivalent per day in 2023, at a ratio of 74% oil and natural gas liquids and 26% natural gas.</p>
<h3>A Deep Dive into Hess's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Hess's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>37.25%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Hess's net margin is impressive, surpassing industry averages. With a net margin of <strong>29.37%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Hess's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>10.31%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Hess's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.99%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Hess's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.98</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Hess: Insights From 7 Financial Analysts

<p>Lam Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) has outperformed the market over the past 15 years by 14.29% on an annualized basis producing an average annual return of 26.62%. Currently, Lam Research has a market capitalization of $118.16 billion. </p>
<p><strong>Buying $100 In LRCX:</strong> If an investor had bought $100 of LRCX stock 15 years ago, it would be worth <strong>$3,513.96</strong> today based on a price of $903.79 for LRCX at the time of writing.</p>
<h3>Lam Research's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634020_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

LRCX

If You Invested $100 In This Stock 15 Years Ago, You Would Have $3,500 Today

<p>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.41) by 7.32 percent. This is a 5 percent increase over losses of $(0.40) per share from the same period last year.  The company reported quarterly sales of $620.00 thousand which missed the analyst consensus estimate of $940.00 thousand by 34.04 percent.  This is a 46.74 percent decrease over sales of $1.16 million the same period last year.</p>


Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Orchestra BioMed Hldgs Q1 EPS $(0.38) Beats $(0.41) Estimate, Sales $620.00K Miss $940.00K Estimate

<p>Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) has outperformed the market over the past 10 years by 12.06% on an annualized basis producing an average annual return of 22.82%. Currently, Lululemon Athletica has a market capitalization of $43.88 billion. </p>
<p><strong>Buying $100 In LULU:</strong> If an investor had bought $100 of LULU stock 10 years ago, it would be worth <strong>$760.15</strong> today based on a price of $348.20 for LULU at the time of writing.</p>
<h3>Lululemon Athletica's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634015_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


LULU

If You Invested $100 In This Stock 10 Years Ago, You Would Have $800 Today

<p>11 analysts have shared their evaluations of Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $111.91, a high estimate of $137.00, and a low estimate of $85.00. Witnessing a positive shift, the current average has risen by 23.28% from the previous average price target of $90.78.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1715634012_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Natera among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$117.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Nowak</td>
<td>Craig-Hallum</td>
<td>Announces</td>
<td>Buy</td>
<td>$117.00</td>
<td>-</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$120.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$85.00</td>
<td>$68.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Natera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Natera's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Natera's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Natera analyst ratings.</strong></a></p>
<h2>Discovering Natera: A Closer Look</h2>
<p>Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.</p>
<h3>Natera: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Natera's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>18.2%</strong> as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Natera's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-18.38%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Natera's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-8.67%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Natera's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-4.65%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.54</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRA

Key Takeaways From Natera Analyst Ratings

<p>Management expects cash burn for the full year 2024 to be approximately&nbsp;$40 million.<br />
&nbsp;</p>


Guidance

HYPR

Hyperfine Expects FY24 Revenue To Be $12M-$15M, Est $12.787M

<p>Today, Terran Orbital Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLAP#NYSE">LLAP</a>) ("Terran Orbital" or the "Company"), a global leader in satellite-based solutions primarily serving the aerospace and defense industries, announced being selected by Lockheed Martin to produce 18 satellite buses for their recent Space Development Agency (SDA) Tranche 2 (T2) Tracking Layer contract.</p>


Contracts

LLAP

Terran Orbital Awarded Subcontract, Selected By Lockheed Martin To Produce 18 Satellite Buses For Their Recent Space Development Agency  Tranche 2 Tracking Layer Contract

CPTN

Cepton Sees FY24 Revenue $15M-$25M Vs $20.267M Est.

BDC Weekly Review: Take Care When Running BDC Screens

Ares Capital: 40+ Big-Yield BDCs Compared (Earnings Season Edition)

Horizon Technology Finance Corporation (HRZN) Q2 2023 Earnings Call Transcript

Building A Balanced Portfolio With Main Street Capital

Preferreds Weekly Review: Chimera Investment Steps Back From The Libor Brink

Horizon Technology Finance (HRZN) Q3 2023 Earnings Call Transcript

Blackstone Secured Lending: Delivering Results With An ~11% Yield

Saratoga Investment (Down Big): 40+ Big-Yield BDCs Compared

Horizon Technology Finance (HRZN) Q4 2023 Earnings Call Transcript

Horizon Technology Finance Corporation (HRZN) Q1 2024 Earnings Call Transcript

ARCC

BBDC

BXSL

CCAP

CSWC

CSWCZ

FDUS

GAIN

GAINL

GAINN

GAINZ

GBDC

GECC

GECCM

GECCO

GECCZ

GLAD

GLADZ

GSBD

HCXY

HRZN

HTFB

HTFC

HTGC

MAIN

MFIC

MRCC

NMFC

OBDC

OCSL

OFSSH

OXSQ

OXSQG

OXSQZ

PFLT

PNNT

PSEC

RWAY

RWAYL

RWAYZ

SSSS

SSSSL

TCPC

TPVG

TRIN

TRINL

TSLX

WHFCL